share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K:重大事件
美股SEC公告 ·  06/03 17:27

Moomoo AI 已提取核心訊息

Illumina, Inc., a biotechnology company, has announced the approval of a Spin-Off of its subsidiary GRAIL, LLC by its board of directors. The Spin-Off will result in the distribution of at least 85.5% of GRAIL's common stock to Illumina's shareholders as a pro rata dividend. This distribution is scheduled to be effective on June 24, 2024, at 12:01 AM New York City time, with GRAIL expected to commence trading on the Nasdaq Global Select Market under the ticker symbol 'GRAL' the following day. Shareholders of Illumina as of the record date, June 13, 2024, will receive one share of GRAIL for every six shares of Illumina they own. The Spin-Off is contingent upon certain conditions outlined in GRAIL's Form 10 registration...Show More
Illumina, Inc., a biotechnology company, has announced the approval of a Spin-Off of its subsidiary GRAIL, LLC by its board of directors. The Spin-Off will result in the distribution of at least 85.5% of GRAIL's common stock to Illumina's shareholders as a pro rata dividend. This distribution is scheduled to be effective on June 24, 2024, at 12:01 AM New York City time, with GRAIL expected to commence trading on the Nasdaq Global Select Market under the ticker symbol 'GRAL' the following day. Shareholders of Illumina as of the record date, June 13, 2024, will receive one share of GRAIL for every six shares of Illumina they own. The Spin-Off is contingent upon certain conditions outlined in GRAIL's Form 10 registration statement with the SEC. In conjunction with the Spin-Off, Illumina anticipates incurring charges between $35 and $50 million, mainly for legal and advisory fees, with the majority expected in Q2 and the remainder by Q3 of 2024. Additionally, the Spin-Off may lead to a potential goodwill impairment for Illumina, which could be recognized following an interim test in Q2 of 2024. The company's balance sheet as of March 31, 2024, shows $1,466 million in goodwill, $561 million in non-amortizing in-process research and development, and $2,092 million in net amortizing intangible assets related to GRAIL.
生物技術公司illumina宣佈董事會批准分拆旗下子公司GRAIL,分拆將以比例股利的方式向illumina股東派發GRAIL至少85.5%的普通股。此分配計劃在2024年6月24日,美國東部時間上午12:01生效,隔日GRAIL將開始在納斯達克全球精選市場上市,股票代碼為“GRAL”。illumina的股東,在記錄日期2024年6月13日,將按照每6股illumina股份換發1股GRAIL股票。GRAIL在美國證券交易委員會(SEC)的10號申報書中以特定條件為前提進行分拆。與分拆相關,illumina預計將承擔3500萬至5000萬美元的費用,主要是法律和顧問費用,其中大部分費用預計在20...展開全部
生物技術公司illumina宣佈董事會批准分拆旗下子公司GRAIL,分拆將以比例股利的方式向illumina股東派發GRAIL至少85.5%的普通股。此分配計劃在2024年6月24日,美國東部時間上午12:01生效,隔日GRAIL將開始在納斯達克全球精選市場上市,股票代碼為“GRAL”。illumina的股東,在記錄日期2024年6月13日,將按照每6股illumina股份換發1股GRAIL股票。GRAIL在美國證券交易委員會(SEC)的10號申報書中以特定條件為前提進行分拆。與分拆相關,illumina預計將承擔3500萬至5000萬美元的費用,主要是法律和顧問費用,其中大部分費用預計在2024年第二季度產生,其餘費用在第三季度產生。此外,分拆可能導致illumina的商譽損失,並可能於2024年第二季度的中期測試後確認。截至2024年3月31日,該公司的資產負債表顯示,商譽金額為14.66億美元,非攤銷的研究和開發費用為5.61億美元,淨攤銷無形資產與GRAIL有關為20.92億美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息